Form 8-K - Current report:
SEC Accession No. 0000950170-25-083046
Filing Date
2025-06-06
Accepted
2025-06-06 16:05:18
Documents
11
Period of Report
2025-06-05
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kura-20250605.htm   iXBRL 8-K 84601
2 EX-99.1 kura-ex99_1.htm EX-99.1 451816
  Complete submission text file 0000950170-25-083046.txt   711727

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kura-20250605.xsd EX-101.SCH 30898
13 EXTRACTED XBRL INSTANCE DOCUMENT kura-20250605_htm.xml XML 4709
Mailing Address 12730 HIGH BLUFF DRIVE, SUITE 400 SAN DIEGO CA 92130
Business Address 12730 HIGH BLUFF DRIVE, SUITE 400 SAN DIEGO CA 92130 (858) 500-8800
Kura Oncology, Inc. (Filer) CIK: 0001422143 (see all company filings)

EIN.: 611547851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37620 | Film No.: 251030539
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)